Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Conway

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 25, 2015
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected PersonsLaurence Brunet, Erica E M Moodie, Jim Young, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2016
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?Sahar Saeed, Erin C Strumpf, Sharon L Walmsley, et al.
CMAJ Open|October 24, 2019
Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV NetworkCarla S Coffin, Alnoor Ramji, Curtis L Cooper, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 25, 2015
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected PersonsLaurence Brunet, Erica E M Moodie, Jim Young, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2016
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?Sahar Saeed, Erin C Strumpf, Sharon L Walmsley, et al.
CMAJ Open|October 24, 2019
Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV NetworkCarla S Coffin, Alnoor Ramji, Curtis L Cooper, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 15